The role of long non-coding RNAs in drug resistance of cancer.,Clinical Genetics

当前位置： X-MOL 学术 › Clin. Genet. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The role of long non-coding RNAs in drug resistance of cancer.
Clinical Genetics ( IF 2.9 ) Pub Date : 2020-06-25 , DOI: 10.1111/cge.13800
He-da Zhang ₁ , Lin-Hong Jiang _{1,

2} , Shan-Liang Zhong ₃ , Jian Li ₄ , Da-Wei Sun ₄ , Jun-Chen Hou ₁ , Dan-Dan Wang ₁ , Si-Ying Zhou ₅ , Jin-Hai Tang ₁

Affiliation

Long non‐coding RNAs (lncRNAs), a class of long RNAs, are longer than 200 nucleotides in length but lack protein‐coding capacity. LncRNAs, as critical genomic regulators, are involved in genomic imprinting regulation, histone modification and gene expression regulation as well as tumor initiation and progression. However, it is also found that lncRNAs are associated with drug resistance in several types of cancer. Drug resistance is an important reason for clinical chemotherapy failure, and the molecular mechanism of tumor resistance is complex, which is a process of multi‐cause, multi‐gene and multi‐signal transduction pathway interaction. Then comprehending the mechanisms of chemoresistance will help find ways to control the tumor progression effectively. Therefore, in this review, we will construct lncRNAs /drug resistance interaction network and shed light on the role of lncRNAs in drug resistance.

中文翻译：

长链非编码 RNA 在癌症耐药性中的作用。

长链非编码 RNA (lncRNA) 是一类长 RNA，长度超过 200 个核苷酸，但缺乏蛋白质编码能力。LncRNAs作为关键的基因组调控因子，参与基因组印记调控、组蛋白修饰和基因表达调控以及肿瘤的发生和发展。然而，也发现 lncRNA 与几种癌症的耐药性有关。耐药是临床化疗失败的重要原因，肿瘤耐药的分子机制复杂，是一个多病因、多基因、多信号转导通路相互作用的过程。然后理解化疗耐药的机制将有助于找到有效控制肿瘤进展的方法。因此，在本次审查中，

更新日期：2020-06-25

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11